This site is intended for healthcare professionals

ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

INTEGRILIN
Thromboembolic disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

INTEGRILIN Rx

Generic Name and Formulations:
Eptifibatide 0.75mg/mL, 2mg/mL; soln for IV inj.

Company:
Merck & Co., Inc.

Therapeutic Use:

Indications for INTEGRILIN:

For acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI), including those undergoing intracoronary stenting.

Adult:

See literature. Use in combination with aspirin and heparin. ACS: 180micrograms/kg IV bolus, followed by a continuous IV infusion of 2micrograms/kg/min until discharge or CABG surgery, up to 72hrs. If PCI planned, continue infusion until discharge, or for up to 18–24hrs after procedure, whichever comes first, allowing up to 96hrs of therapy. PCI: 180micrograms/kg IV bolus followed by 2micrograms/kg/min infusion; repeat 180micrograms/kg IV bolus 10mins after the 1st bolus; continue infusion until discharge, or for up to 18–24hrs, whichever comes first, minimum 12hr-infusion recommended. CrCl <50mL/min: reduce infusion rate to 1microgram/kg/min.

Children:

Not recommended.

Contraindications:

Bleeding diathesis or active abnormal bleeding within previous 30 days. Severe uncontrolled hypertension. Major surgery within previous 6 weeks. History of stroke within 30 days or any history of hemorrhagic stroke. Concomitant parenteral GP IIb/IIIa inhibitors. Renal dialysis.

Warnings/Precautions:

See literature. Discontinue if uncontrolled bleeding occurs. Platelet count <100,000/mm3. Properly care for femoral artery access site to minimize bleeding. Minimize other arterial and venous punctures, IM inj, catheter use, intubation, NG tubes, to lower bleeding risk; avoid use of non-compressible IV access sites. Do baseline platelet counts, hemoglobin, hematocrit, others and monitor during therapy (see literature). Discontinue if confirmed thrombocytopenia occurs. Renal insufficiency. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

Antiplatelet effects may be potentiated by thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole.

Pharmacological Class:

Antiplatelet.

Adverse Reactions:

Bleeding, intracranial hemorrhage, stroke, thrombocytopenia, hypersensitivity reactions, hypotension.

Generic Availability:

YES

How Supplied:

Vial 0.75mg/mL (100mL)—1; 2mg/mL (10mL, 100mL)—1

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.


Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Groin swelling - red flag symptomsExternal web site

This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...

0.50 Credits
Red flags

Erectile dysfunction - red flag symptomsExternal web site

This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...

0.50 Credits
Red flags

Headache - red flag symptomsExternal web site

Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Basal cell carcinoma: clinical reviewExternal web site

In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...

1.50 Credits
Clinical Review

Cardiomyopathy: clinical reviewExternal web site

This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...

1.50 Credits
Clinical Review

Parkinson's disease: clinical reviewExternal web site

Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »